Meta-analysis shows dual ICI therapy improves survival in advanced metastatic non-small cell lung cancer
New analysis shows dual immune therapy helps patients with advanced lung cancer live longer and delays disease growth
This meta-analysis evaluates dual immune checkpoint inhibitor therapy versus control treatments in patients with advanced or metastatic non-…
A large review of 6,369 patients found that using two immune checkpoint drugs together improved survival time compared to standard treatment…
Post hoc reanalysis suggests stereotactic radiotherapy may improve local control in medically inoperable Stage I non-small cell lung cancer
New analysis gives hope for early lung cancer patients who cannot have surgery
This post hoc Bayesian reanalysis of the LUSTRE trial evaluated stereotactic radiotherapy versus conventional radiotherapy in medically inop…
A new statistical review suggests a focused radiation approach may better control early lung cancer for patients who cannot undergo surgery.
Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
Combining checkpoint inhibitors with chemotherapy helps more lung cancer patients get surgery safely
This meta-analysis synthesized outcomes from 1,885 patients with potentially resectable non-small cell lung cancer who received neoadjuvant …
A review of 1,885 patients found that adding immune therapy to standard chemo before surgery helped many get clean operations. About one in …
Narrative review explores Vaccinia virus therapy for non-small cell lung cancer with noted delivery challenges
Vaccinia Virus May Turn Cold Lung Tumors Into Hot Targets For Immune Attack
This narrative review examines preclinical and early clinical data regarding Vaccinia virus therapy for non-small cell lung cancer. The auth…
A repurposed virus from smallpox vaccines might finally help the immune system attack lung cancer tumors that have stopped responding to sta…
FDA Approves Lazcluze (lazertinib) with Amivantamab for EGFR-Mutant NSCLC
FDA approves new lung cancer pill Lazcluze for certain patients.
FDA approved Lazcluze (lazertinib) in combination with amivantamab for first-line treatment of adults with locally advanced or metastatic NS…
The FDA approved Lazcluze (lazertinib) with another drug for adults with a common type of advanced lung cancer. This new oral treatment is f…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer
A Hidden Protein Switch May Fuel Cancer Growth and Drug Resistance
This narrative review addresses multiple malignancies including hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pa…
A single protein called PRMT3 helps multiple cancers grow, hide from the immune system, and resist chemotherapy, making it a promising new t…
Case report and review highlights ultrasound-guided microwave ablation for metastatic breast cancer in a single patient
Microwave Ablation Controls Breast Metastasis for Three Years
This case report and review of the literature describes ultrasound-guided microwave ablation in a 59-year-old female with metastatic breast …
A single session of microwave ablation kept a breast cancer metastasis under control for three years with no major side effects.
Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
Real-world data confirms pembrolizumab offers long-term survival for advanced lung cancer patients
A systematic review and meta-analysis of real-world studies evaluated first-line pembrolizumab monotherapy for advanced NSCLC with high PD-L…
New data from thousands of patients shows pembrolizumab provides reliable long-term survival for advanced lung cancer without major safety s…
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
This Phase 3 trial evaluated pembrolizumab monotherapy against chemotherapy in Chinese patients with previously untreated locally advanced o…
A five-year look at a Chinese lung cancer trial shows pembrolizumab improved survival compared to chemotherapy for patients with high PD-L1 …
Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
New combo therapy extends life for advanced small cell lung cancer patients
This multi-center, single-arm phase II trial evaluated maintenance toripalimab plus anlotinib in 20 patients with extensive-stage small cell…
A new drug pair extends life for advanced lung cancer patients by changing how their immune system fights back
Research across Cancer
Related studies from across the Cancer family.
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
Narrative review outlines multimodal decision-making for EGFR-mutant NSCLC with leptomeningeal metastasis
Doctors outline a pathway for treating lung cancer that spreads to the brain
This narrative review addresses patients with EGFR-mutant non-small cell lung cancer who develop resistance to tyrosine kinase inhibitors an…
This review outlines a clinical pathway to help physicians personalize treatment for lung cancer patients with brain spread.
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers
FDA approves Enhertu for several types of HER2 positive cancers.
FDA approved Enhertu for several indications including HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow breast cancer, HER…
The FDA has approved Enhertu for multiple cancers, including breast, lung, stomach, and other solid tumors that have a specific protein call…
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
Review of IVIG and bronchoscopic interventions for pediatric EBV-SMT in immunodeficiency
A rare lung tumor in a boy with immune issues may need IVIG and bronchoscopic procedures
This case report review describes a 10-year-old boy with congenital immunodeficiency and an Epstein–Barr virus-associated smooth muscle tumo…
A single case report suggests IVIG and bronchoscopic procedures might help a rare lung tumor in children with immune problems, though recurr…
Deep hyperthermia with tislelizumab and chemotherapy in advanced squamous NSCLC
Deep Heat Plus Drug Boosts Lung Cancer Response Rates
This retrospective cohort study of 100 patients with advanced squamous NSCLC evaluated deep hyperthermia combined with tislelizumab and chem…
Adding deep heat to standard lung cancer treatment improved response rates significantly while keeping safety levels the same as standard ch…
Consolidation immunotherapy shows no survival benefit over induction alone in stage III non-small cell lung cancer
Adding immunotherapy after chemo may not help stage III lung cancer
This retrospective cohort study evaluated 196 patients with stage III non-small cell lung cancer across 4 hospitals.
Stage III lung cancer patients saw no clear survival gain when immunotherapy was added after chemo and radiation.
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors.
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Modified thin-slab volume rendering improves diagnostic performance for pneumonic-type lung cancer and inflammatory pneumonia
New Imaging Trick Tells Cancer and Pneumonia Apart
This retrospective cohort study evaluated modified thin-slab volume rendering (tsVR) with densitometry-derived thresholds against convention…
Doctors can now tell aggressive lung cancer apart from pneumonia more accurately using a simple tweak to CT scans that highlights subtle dif…
Double 8F ultrafine chest tubes reduced pain and complications compared to standard tubes in lung tumor patients
Smaller tubes mean less pain for lung tumor patients after surgery
This retrospective multicenter cohort study evaluated 1,076 lung tumor patients who underwent U-VATS.
Lung surgery patients feel significantly less pain and face lower bleeding risks when doctors use ultrafine drainage tubes instead of regula…
Questions about Extensive-Stage Small-Cell Lung Cancer
How does adding a PD-1 inhibitor to platinum-etoposide improve survival in extensive-stage small-cell lung cancer?
Adding a PD-1 inhibitor to platinum-etoposide improves overall survival by about 26% (HR 0.74) and progression-free survival by about 32% (HR 0.68) in ES-SCLC, based on meta-analyses of phase III trials.
Full answer →Does toripalimab plus anlotinib maintenance show promise for extensive-stage small-cell lung cancer?
Yes, a phase II trial found toripalimab plus anlotinib maintenance after first-line chemo led to median progression-free survival of 8.18 months and overall survival of 23.05 months in ES-SCLC.
Full answer →